Table of Content

Introduction
Executive Summary
Spinal muscular atrophy: Overview
? Causes
? Mechanism of Action
? Signs and Symptoms
? Diagnosis
? Disease Management
Pipeline Therapeutics
? Comparative Analysis
Therapeutic Assessment
? Assessment by Product Type
? Assessment by Stage and Product Type
? Assessment by Route of Administration
? Assessment by Stage and Route of Administration
? Assessment by Molecule Type
? Assessment by Stage and Molecule Type
Spinal muscular atrophy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
? Comparative Analysis
Drug name: Company name
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
? Comparative Analysis
Apitegromab: Scholar Rock
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..

Early Stage Products (Phase I)
? Comparative Analysis
BIIB 110: Biogen
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Preclinical and Discovery Stage Products
? Comparative Analysis
ASCJ 9: AndroScience Corporation
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..

Inactive Products
? Comparative Analysis
Spinal muscular atrophy Key Companies
Spinal muscular atrophy Key Products
Spinal muscular atrophy- Unmet Needs
Spinal muscular atrophy- Market Drivers and Barriers
Spinal muscular atrophy- Future Perspectives and Conclusion
Spinal muscular atrophy Analyst Views
Spinal muscular atrophy Key Companies
Appendix



List of Figures

Figure 1 Total Products for Spinal muscular atrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

List of Tables

Table 1 Total Products for Spinal muscular atrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products